Gilead Sciences, Inc.
About Gilead Sciences, Inc.
Gilead Sciences is a biopharmaceutical company that discovers, develops, and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.
1800 articles with Gilead Sciences, Inc.
-
As is typical, the second day of the JP Morgan Annual Healthcare Conference—conducted virtually this year because of the pandemic—had plenty of news from the largest biopharma companies globally.
-
BioSpace takes a look at some of the announcements that occurred Monday and will continue to update throughout the week.
-
Gilead and Vir Biotechnology Establish Clinical Collaboration to Explore Combination Strategies for Functional Cure for Chronic Hepatitis B Virus
1/12/2021
First Phase 2 clinical trial to combine immunomodulation and antigen suppression approaches in HBV cure research
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for January 12, 2021.
-
Gilead Sciences Announces Updated 2020 Guidance
1/11/2021
Gilead Sciences, Inc. announced the company has revised certain elements of its full year 2020 guidance.
-
Top 2020 Biopharma M&A Deals
1/6/2021
BioSpace highlights a number of the key M&A deals struck over the past 12 months. -
Top 12 Biotech Companies Hiring Now
1/5/2021
The new year is here and the biotech job market is hot! A new year, a new you, a new job? -
Gilead Sciences to Present at the 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021
12/21/2020
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Daniel O’Day, Gilead’s Chairman and Chief Executive Officer, will provide an overview of the company at the 39 th Annual J.P. Morgan Healthcare Conference on Monday, January 11 at 12:40 p.m. Pacific Time. The live webcast can be accessed at the company’s Investors page at http://investors.g
-
Kite’s Tecartus™ (KTE-X19) Granted Conditional Marketing Authorization for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma in Europe
12/16/2020
Tecartus is First CAR T Therapy in Relapsed or Refractory MCL and Kite Becomes the First Company with Multiple Approved Cell Therapies in Europe
-
A little more than one year after Gilead Sciences and Galapagos NV announced intentions to seek regulatory approval for Jyseleca (filgotinib) as a treatment for rheumatoid arthritis, the companies have pulled the plug on that goal.
-
Gilead and Galapagos Announce New Commercialization and Development Agreement for Jyseleca® (Filgotinib)
12/15/2020
Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & Nasdaq: GLPG) today announced that the companies have agreed to amend their existing arrangement for the commercialization and development of Jyseleca (filgotinib).
-
Gilead Advances Oncology Portfolio With New Data From Phase 3 ASCENT Trial of Trodelvy® in Metastatic Triple Negative Breast Cancer
12/10/2020
Gilead Sciences, Inc. (Nasdaq: GILD) is presenting new data from the Phase 3 ASCENT trial of Trodelvy® (sacituzumab govitecan-hziy) in metastatic triple-negative breast cancer (mTNBC) at the 2020 San Antonio Breast Cancer Symposium being held virtually December 8-11, 2020.
-
Gilead Sciences to Acquire MYR GmbH
12/10/2020
Gilead Sciences, Inc. (Nasdaq: GILD) and MYR GmbH, a German biotechnology company focused on the development and commercialization of therapeutics for the treatment of chronic hepatitis delta virus (HDV), today announced that the companies have entered into a definitive agreement pursuant to which Gilead will acquire MYR for approximately €1.15 billion in cash,
-
Gilead Sciences bolstered its capabilities in treating Hepatitis and other liver diseases with the €1.15 billion ($1.4 billion) cash acquisition of Germany-based Myr GmbH, a company focused on developing therapies for treatment of chronic hepatitis delta virus (HDV), the most severe form of viral...
-
Gilead Announces Racial Equity Community Impact Fund to Support Black Communities Across United States
12/9/2020
Gilead Sciences, Inc. (Nasdaq: GILD) today announced the launch of its Racial Equity Community Impact Fund, which will support high-impact organizations working to tackle racial inequities affecting Black communities across the United States
-
Jeffrey A. Bluestone Joins Gilead Sciences’ Board of Directors
12/8/2020
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that Jeffrey A. Bluestone, PhD, has been appointed to the company’s Board of Directors.
-
ASH 2020: CRISPR and Vertex's Potential Cure for Sickle Cell Disease and More Glimmers of Hope
12/7/2020
The American Society of Hematology (ASH) Annual Meeting & Exposition began December 5, and there were numerous presentations, abstracts and posters. Here’s a look at some of the stories out of the first day. -
Magrolimab Demonstrates Clinical Responses in Ongoing Phase 1b Trial of Previously Untreated Acute Myeloid Leukemia Patients
12/6/2020
Similar Overall and Complete Response Rates Observed Across Frontline AML Patients Ineligible for Intensive Chemotherapy and in High Unmet Need Patients with TP53-Mutant AML
-
Yescarta® Shows Positive Results as a First-Line Treatment for Patients With High-Risk Large B-cell Lymphoma
12/6/2020
85 Percent of Patients Responded to a Single Infusion of Yescarta, Including 74 Percent of Patients Achieving Complete Response
-
Yescarta® Is First CAR T-cell Therapy to Demonstrate High Response Rates and Durable Clinical Benefit in a Pivotal Indolent Non-Hodgkin Lymphoma Study
12/5/2020
Primary Analysis Supports Supplemental Biologics License Application (sBLA) for Yescarta Currently Under Priority Review by the U.S. Food & Drug Administration (FDA)